ERBB2 and neoplasm: We found that tumors with lower levels of PPP2R2B expression showed significantly less size reduction after two cycles of neoadjuvant treatment compared to tumors with higher expression of PPP2R2B (P = 0.0080; Fig. 1e), supporting the notion of PPP2R2B downregulation being associated with poor tumor response to anti-HER2 treatment.